Core gene chip and probe suitable for general survey of colon cancer

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a core gene chip and a probe suitable for general survey of colon cancer, and the core gene chip and the probe are used for solving the technical problem of low detection accuracy rate in the prior art. The core gene chip suitable for general survey of colon cancer comprises a solid phase carrier and a group of probes fixed on the solid phase carrier, the group of probes comprises nucleotide sequences shown by SEQ ID NO:1-SEQ ID NO:24 in the sequence table; the core gene probe suitable for general survey of colon cancer by the gene chip is characterized by comprising the nucleotide sequences shown by SEQ ID NO:1-SEQ ID NO:24 in the sequence table. The core gene chip and the probe have the advantages that firstly, early diagnosis of colon cancer is realized, the survival rate of cancerous person is greatly improved; secondly, due to the promotion of the chip technology, the general survey level of the colon cancer is improved to molecular diagnosis from clinical physical examination, so that the general survey level and quality are greatly improved; thirdly, for the promotion of chip molecular diagnosis technology in general survey of colon cancer, passive general survey of the cancer is replaced by active prediction and early treatment.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a gene chip, in particular to a core gene chip and a probe suitable for general screening of colon cancer. Background technique [0002] Colon cancer refers to the malignant lesion of the colon mucosal epithelium under the action of various carcinogenic factors such as environment or heredity, and is one of the common malignant tumors. The onset of colon cancer is insidious, and there are often no obvious clinical manifestations in the early stage. The disease progresses slowly. When obvious symptoms appear, most of them have reached the middle and late stages. The mortality rate is second only to lung cancer and liver cancer, accounting for the third place among malignant tumors in my country. By 2020, the global cancer incidence rate will increase by 50%, that is, 15 million new cancer patients will be added every year, and 20% of the new cancer patients will be in China. 20%...

AI Technical Summary

Problems solved by technology

[0007] However, there are two obvious design deficiencies in the existing gene chips, especially those used for tumor molecular diagnosis. First, many technology companies list hundreds or even thousands of genes on one chip, which not only The cost of making a gene chip is high, and it is easy to cause high cost during the detection process, resulting in a high false positive rate during analysis, which greatly reduces the promotion of the gene chip method in clinical tumor detection; second, Unreasonable selection of detected genes makes the sensitivity of detecting cancer not meet clinical requirements

Images